alexa Structure Guided Design Of A Therapeutic Inhibitor Of SALL4-NuRD In Liver Cancer
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Global Summit on Oncology & Cancer
May 25-27, 2017 Osaka, Japan

Bee Hui Liu
Cancer Science Institute of Singapore, Singapore
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956-C1-100
Nuclear factors are often considered undruggable and conventional high throughput screening of small molecules has resulted in limited success. SALL4 is a nuclear factor that is specifically expressed in fetal cell, where it is vital to developmental events and the maintenance of stem cell pluripotency. SALL4 has recently emerged as a key player in hepatocellular carcinoma. In cancer cells, SALL4 recruits NURD to PTEN promoter, resulting in histone deacetylation and transcriptional repression. However, the binding mechanism of SALL4 to NuRD remained elusive. Understanding the mechanism will enable the development of specific inhibitors against the SALL4-NURD interaction in liver cancer, a malignancy with fast increasing incidence and mortality rate, with no suitable treatment regime. Here, we report the development of a potent anti-tumor therapeutic SALL4 peptide (named FFW), based on our elucidation of the crystal structure of SALL4-RBBp4 complex at 2.7Å. We show that FFW has 56- fold increase in target affinity compared to wild-type peptide, and exhibits potent anti-tumor activity in xenograft mouse models (tumor growth inhibition=85%), supporting FFW as a highly viable drug candidate. With further refinement, this FFW peptide could potentially fulfill the unmet need in liver cancer and other malignancies characterized by SALL4 expression. This mode of structural analysis to target “undruggable” nuclear factors could also prove a highly viable approach in other areas of cancer research.

Bee Hui Liu, PhD, is a Molecular Biologist working in the stream of Translational Medicine. She received her PhD from National University of Singapore and is currently a Post-doctoral fellow at Prof. Daniel Tenen’s Laboratory in Cancer Science Institute of Singapore. She is interested in developing therapeutic agents against epigenetic complexes in cancer. She solved the first SALL4-RBBp4 structure and invented therapeutic peptides targeting this particular complex that specifically elevated in a subset of liver cancer. She also heads a multi-disciplinary collaborative team of local and international scientists, spearheading small molecule- and fragment based- drug screening projects on liver cancer.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version